B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TYMS

MOLECULAR TARGET

thymidylate synthetase

UniProt: P04818NCBI Gene: 729810 compounds

TYMS (thymidylate synthetase) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TYMS

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1methotrexate6.00404
2raltitrexed3.5835
3Pemetrexed3.0420
4Fluorodeoxyuridylate 5-Fluoro-2'-deoxyuridylate.2.8316
5phenolphthalein2.309
6Methotrexate1.393
7Capecitabine1.102
8Cytarabine0.691
9Thymidine Monophosphate 5-Thymidylic acid.0.691
10Trifluridine0.691

About TYMS as a Drug Target

TYMS (thymidylate synthetase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented TYMS interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TYMS inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.